S.B. No. 2308 establishes a consortium dedicated to conducting clinical trials for the drug ibogaine, aiming to obtain FDA approval for its use in treating opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions. The bill introduces Chapter 491 to the Health and Safety Code, detailing the consortium's formation, membership requirements—including a drug developer, an institution of higher education, and a hospital—and the responsibilities of the lead institution, which will manage administrative functions and submit funding proposals for the trials. The bill also outlines the selection process for the consortium, proposal submission requirements, and funding mechanisms, mandating quarterly progress and financial reports while ensuring that at least 20% of generated revenue is allocated to the state.

Additionally, the bill includes a new subchapter regarding the administration of ibogaine, contingent upon FDA approval, requiring that a licensed physician supervise its administration in a hospital or licensed healthcare facility. It clarifies that the bill does not prevent physicians from administering ibogaine in compliance with federal law. The bill also allows for the delay of implementation if a federal waiver or authorization is needed, and mandates that the Health and Human Services Commission begin accepting proposals from consortiums within 60 days of the bill's effective date. The bill will take effect immediately with a two-thirds vote from both houses or on September 1, 2025, if not passed.

Statutes affected:
Introduced: ()
Senate Committee Report: ()
Engrossed: ()
House Committee Report: ()
Enrolled: ()